• RCCSE中国核心学术期刊(A+)
  • 中国百强报刊
  • 百种中国杰出学术期刊
  • 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国自然科学类核心期刊
  • 中国科技论文统计源期刊
  • 中华医学会优秀期刊
  • 中国精品科技期刊顶尖学术论文(5000)项目来源期刊
  • 入选中国高质量科技期刊分级目录(消化病学)T1级
  • 入选《中国学术期刊影响因子年报(自然科学与工程技术)》Q1区
  • 入选《科技期刊世界影响力指数(WJCI)报告(2022)》
  • RCCSE中国核心学术期刊(A+)
  • 中国百强报刊
  • 百种中国杰出学术期刊
  • 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国自然科学类核心期刊
  • 中国科技论文统计源期刊
  • 中华医学会优秀期刊
  • 中国精品科技期刊顶尖学术论文(5000)项目来源期刊
  • 入选中国高质量科技期刊分级目录(消化病学)T1级
  • 入选《中国学术期刊影响因子年报(自然科学与工程技术)》Q1区
  • 入选《科技期刊世界影响力指数(WJCI)报告(2022)》
Shang Minjie, Zhang Jungang, Gu Zongting, et al. Clinical efficacy of immunotherapy plus target therapy for preventing postoperative recurr-ence of hepatocellular carcinoma after associating liver partition and portal vein ligation for staged hepatectomy[J]. Chinese Journal of Digestive Surgery, 2023, 22(2): 281-285. DOI: 10.3760/cma.j.cn115610-20221123-00708
Citation: Shang Minjie, Zhang Jungang, Gu Zongting, et al. Clinical efficacy of immunotherapy plus target therapy for preventing postoperative recurr-ence of hepatocellular carcinoma after associating liver partition and portal vein ligation for staged hepatectomy[J]. Chinese Journal of Digestive Surgery, 2023, 22(2): 281-285. DOI: 10.3760/cma.j.cn115610-20221123-00708

Clinical efficacy of immunotherapy plus target therapy for preventing postoperative recurr-ence of hepatocellular carcinoma after associating liver partition and portal vein ligation for staged hepatectomy

Funds: 

Major Projects Jointly Constructed by Zhejiang Provincial Ministry WKJ-ZJ-1901

More Information
  • Corresponding author:

    Tao Ran, Email: taohdac9@yahoo.com

  • Received Date: November 22, 2022
  • Available Online: June 24, 2024
  • Surgical resection in patients with advanced primary carcinoma of liver has high risks of early recurrence and incidence of portal vein tumor thrombus, caused by insufficient resi-dual liver volume after two-steps hepatotomy. At present, the treatment for patients with advanced primary carcinoma of liver is limited, thus can't satisfy the requirement of patient for treatment. The authors introduce the clinical experience of a patient with hepatocellular carcinoma and insufficient residual liver volume who underwent preventive immunotherapy plus target therapy after associa-ting liver partition and portal vein ligation for staged hepatectomy, in order to provide reference for relevant treatment.

  • [1]
    郑树国,旷钥文.腹腔镜限量解剖性肝切除术的理念与实践[J].中华消化外科杂志,2022,21(5):586-590. DOI: 10.3760/cma.j.cn115610-20220506-00255.
    [2]
    中华医学会肝病学分会肝癌学组.HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J].临床肝胆病杂志,2021,37(10):2292-2302. DOI:10.3969/j.issn.1001-5256. 2021.10.008.
    [3]
    林伯辉,区奕猛.联合肝脏离断和门静脉结扎的二步肝切除术在不可切除肝细胞癌中的应用[J].临床肝胆病杂志,2021,37(1):180-183. DOI: 10.3969/j.issn.1001-5256.2021.01.039.
    [4]
    国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究》专家组.肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)[J].中国实用外科杂志,2021,41(1):20‑30. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.03.
    [5]
    中国抗癌协会肝癌专业委员会胆管癌协作组.原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J].中华消化外科杂志,2022,21(10):1269‑1301. DOI: 10.3760/cma.j.cn115610-20220829-00476.
    [6]
    杨逸涵,李婉慈,仲斌演,等.经肝动脉化疗栓塞术联合卡瑞利珠单抗及阿帕替尼治疗中晚期肝细胞癌的效果及安全性分析[J].临床肝胆病杂志,2022,38(12):2755-2760. DOI: 10.3969/j.issn.1001-5256.2022.12.014.
    [7]
    IshikawaM, NishiokaM, HanakiN, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries[J]. World J Surg Oncol,2009,7:7. DOI:10.11 86/1477-7819-7-7.
    [8]
    DąbrowskaAM, SłotwińskiR. The immune response to surgery and infection[J]. Cent Eur J Immunol,2014,39(4):532‑537. DOI: 10.5114/ceji.2014.47741.
    [9]
    冀柏宇,郝芬林,海江涛,等.经肝动脉化疗栓塞联合局部消融治疗外科术后复发性肝癌的预后分析[J].临床肝胆病杂志,2022,38(7):1572-1576. DOI:10.3969/j.issn.1001-5256. 2022.07.021.
    [10]
    PostowMA, SidlowR, HellmannMD. Immune‑related adverse events associated with immune checkpoint blockade[J]. N Engl J Med,2018,378(2):158‑168. DOI:10.1056/NEJMra 1703481.
    [11]
    MichotJM, BigenwaldC, ChampiatS, et al. Immune-rela-ted adverse events with immune checkpoint blockade: a comprehensive review[J]. Eur J Cancer,2016,54:139‑148. DOI: 10.1016/j.ejca.2015.11.016.
    [12]
    FinnRS, QinS, IkedaM, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894‑1905. DOI:10.1056/NEJMoa19 15745.
    [13]
    刘耀鸿,林宜圣,杨荣焕,等.仑伐替尼联合肝动脉化疗栓塞术对中晚期原发性肝癌患者近期疗效、T淋巴细胞免疫功能及预后的影响[J].临床误诊误治,2022,35(7):60-63. DOI: 10.3969/j.issn.1002-3429.2022.07.015.
    [14]
    孙志民,徐永建,华小斌,等.原发性肝细胞癌根治术后行预防性TACE的应用价值及复发危险因素分析[J].中国现代普通外科进展,2021,24(6):474-477.
    [15]
    XiaoY, PengL, XuH, et al. Mechanism of liver regeneration during ALPPS[J]. Front Cell Dev Biol,2022,10:916286. DOI: 10.3389/fcell.2022.916286.
    [16]
    柴梦音,寇卜心,伏志,等.索拉非尼通过调控Runt相关转录因子3-血管内皮生长因子通路抑制肝癌血管生成[J].中华肝脏病杂志,2022,30(7):770-776. DOI:10.3760/cma.j.cn 501113-20201221-00670.
    [17]
    OlthofPB, BuettnerS, SchaddeE. The relevance of the liver volume increase after ALPPS[J]. Liver Int,2022,42(12):2907. DOI: 10.1111/liv.15376.
    [18]
    胡亚秋,汪妮,冉锡萍,等.评估免疫检查点抑制剂为基础的联合治疗在原发性肝癌患者中肝损伤发生情况的真实世界研究[J].中华肝脏病杂志,2022,30(1):57-62. DOI:10. 3760/cma.j.cn501113-20210910-00466.
    [19]
    Murtha‑LemekhovaA, FuchsJ, SchulzE, et al. Pushing the limit of liver regeneration‑safety and survival after mono-segment‑ALPPS: systematic review and individual patient data meta‑analysis[J]. HPB (Oxford),2022,24(3):353‑358. DOI: 10.1016/j.hpb.2021.06.427.
    [20]
    宁会彬,李宽,尚佳.免疫治疗新时代下晚期肝癌患者的希望之路[J].中华肝脏病杂志,2021,29(4):301-303. DOI:10. 3760/cma.j.cn501113-20210402-00158-1.
    [21]
    Lopez‑LopezV, LineckerM, CruzJ, et al. Liver growth prediction in ALPPS‑a multicenter analysis from the international ALPPS registry[J]. Liver Int,2022,42(12):2815-2829. DOI: 10.1111/liv.15287.
    [22]
    CiriaR, BriceñoJ. The ALPPS procedure‒as limited procedures as possible, leads to improved survival[J]. Hepatobiliary Surg Nutr,2022,11(4):636‑639. DOI: 10.21037/hbsn-22-180.
    [23]
    程笑,陈锦章,郭亚兵.肝癌分子靶向药对免疫系统的调节作用[J].中华肝脏病杂志,2021,29(10):1031-1034. DOI:10. 3760/cma.j.cn501113-20191006-00363.
    [24]
    ByrneM, RuffoloLI, Hernandez‑AlejandroR. ALPPS and the endless pursuit of hepatic resectability[J]. Hepatobiliary Surg Nutr,2022,11(5):732‑734. DOI: 10.21037/hbsn-22-357.
    [25]
    LiuJG, WangJ, SunW, et al. ALPPS in the treatment of liver cancer with insufficient future liver remnant[J]. Hepatobiliary Pancreat Dis Int,2021,20(4):400‑402. DOI: 10.1016/j.hbpd.2021.04.003.
    [26]
    BoteaF, BarcuA, VerdeaC, et al. Regenerative liver surgery-ALPPS and associated techniques[J]. Chirurgia (Bucur),2021,116(4):387‑398. DOI: 10.21614/chirurgia.116.4.387.
    [27]
    MichalK, SauM, TamaraGMH,et al. A better route to ALPPS: minimally invasive vs open ALPPS[J]. Surg Endosc,2020,34(6):2379‑2389. DOI: 10.1007/s00464-020-07437-3.
    [28]
    PengC, LiC, LiuC, et al. The outcome of the HCC patients underwent ALPPS: retrospective study[J]. Medicine (Baltimore),2019,98(38):e17182. DOI: 10.1097/MD.0000000000017182.
    [29]
    BerardiG, GuglielmoN, ColasantiM,et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced hepatocellular carcinoma with macrovascular invasion[J]. Updates Surg,2022,74(3):927‑936. DOI: 10.1007/s13304-022-01277-7.

Catalog

    Article views (462) PDF downloads (0) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return